Cara Therapeutics to Announce Third Quarter 2021 Financial Results on November 8, 2021

Rhea-AI Summary

Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on alleviating pruritus through kappa opioid receptor targeting, will host a conference call on November 8, 2021, at 4:30 p.m. ET. The call will report Q3 2021 financial results and provide corporate updates. Participants can join by phone or via a live audio webcast available on the company's website. KORSUVA™ (CR845/difelikefalin), a first-in-class KOR agonist, received FDA approval for treating moderate-to-severe pruritus associated with chronic kidney disease on August 23, 2021.

Positive

• FDA approval of KORSUVA Injection for chronic kidney disease-related pruritus on August 23, 2021.
• Ongoing Phase 2 trials for oral KORSUVA in various pruritus indications.

Negative

• None.

STAMFORD, Conn., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the Company will host a conference call and live audio webcast on Monday, November 8, 2021 at 4:30 p.m. ET to report third quarter 2021 financial results and provide a corporate update.

To participate in the conference call, please dial (855) 445-2816 (domestic) or (484) 756-4300 (international) and refer to conference ID 1480703. A live webcast of the call can be accessed under “Events & Presentations” in the News & Investors section of the Company’s website at www.CaraTherapeutics.com.

An archived webcast recording will be available on the Cara website beginning approximately two hours after the call.

About Cara Therapeutics

Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs. Cara is developing a novel and proprietary class of product candidates, led by KORSUVA™ (CR845/difelikefalin), a first-in-class KOR agonist that targets the body’s peripheral nervous system, as well as certain immune cells. KORSUVA Injection was approved by the U.S. Food and Drug Administration (FDA) for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis on August 23, 2021. Oral KORSUVA has completed Phase 2 trials for the treatment of pruritus in patients with CKD and atopic dermatitis and is currently in Phase 2 trials in primary biliary cholangitis and notalgia paresthetica patients with moderate-to-severe pruritus.

MEDIA CONTACT:
Annie Spinetta
6 Degrees
973-768-2170
aspinetta@6degreespr.com

INVESTOR CONTACT:
Janhavi Mohite
Stern Investor Relations, Inc.
212-362-1200
janhavi.mohite@SternIR.com

FAQ

What are the financial results for Cara Therapeutics in Q3 2021?

Q3 2021 financial results will be reported during the conference call on November 8, 2021.

What is the significance of KORSUVA for Cara Therapeutics?

KORSUVA is a first-in-class KOR agonist with FDA approval for treating pruritus in chronic kidney disease patients.

When will Cara Therapeutics' conference call take place?

The conference call is scheduled for November 8, 2021, at 4:30 p.m. ET.

How can I access the conference call for Cara Therapeutics?

You can participate by phone or access the live audio webcast on the company's website.